(Alliance News) - Arix Bioscience PLC on Wednesday said its portfolio company Iterum Therapeutics PLC has reported topline results from one of its three third-phase trials for sulopenem.
Sulopenem is Iterum's lead compound and novel antibiotic for the treatment of multi-drug resistant infections.
Arix said the full body of evidence from the trial confirmed overall safety profile and suggested that treatment with sulopenem may result in clinically important benefits in complicated intra-abdominal infections.
However, the investment firm noted that the trial narrowly missed its primary endpoint of clinical response on day 28, by one patient.
Arix shares were trading 0.2% lower in London on Wednesday at 114.80 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
